| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a synthetic intermediate, Boc-Asp(OcHx)-OH has no biological target. Its role is to provide aspartic acid residues in peptide chains with enhanced lipophilicity. The Boc protecting group enables selective reactions during peptide chain assembly. The cyclohexyl ester modification imparts enhanced lipophilicity.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The in vitro activity of Boc-Asp(OcHx)-OH is measured by coupling efficiency in peptide synthesis. The compound demonstrates high coupling efficiency. Purity is assessed by HPLC (≥98%). No inherent biological activity is observed. |
| ln Vivo |
In vivo activity is not applicable.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cellular) experimental workflow involves standard peptide synthesis procedures. A typical workflow: dissolve Boc-Asp(OcHx)-OH in DMF, add coupling reagents, then add amine component. Monitor by TLC. Purify by chromatography. Characterize by NMR and MS. The compound is used as an organic synthesis intermediate and pharmaceutical intermediate.
|
| Cell Assay |
In vitro cell-based experimental workflows are not performed on this compound.
|
| Animal Protocol |
In vivo animal experiments are not applicable.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties have not been characterized.
|
| Toxicity/Toxicokinetics |
The toxicological data are limited. Standard laboratory safety practices should be followed.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
Boc-Asp(OcHx)-OH is a protected derivative of the amino acid aspartic acid, tailored for sophisticated peptide synthesis. The unique β-cyclohexyl ester modification imparts enhanced lipophilicity. The compound is used in peptide synthesis and drug development. It is not a drug and has no clinical trials or approvals. The compound is for research use only. The compound is available from multiple suppliers.
|
| Molecular Formula |
C15H25NO6
|
|---|---|
| Molecular Weight |
315.36
|
| Exact Mass |
315.168
|
| CAS # |
73821-95-1
|
| PubChem CID |
7009416
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
483.5±40.0 °C at 760 mmHg
|
| Melting Point |
93-95 °C
|
| Flash Point |
246.2±27.3 °C
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
| Index of Refraction |
1.499
|
| LogP |
3.55
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
22
|
| Complexity |
409
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)(C)OC(=O)N[C@@H](CC(=O)OC1CCCCC1)C(=O)O
|
| InChi Key |
NLPQIWFEEKQBBN-NSHDSACASA-N
|
| InChi Code |
InChI=1S/C15H25NO6/c1-15(2,3)22-14(20)16-11(13(18)19)9-12(17)21-10-7-5-4-6-8-10/h10-11H,4-9H2,1-3H3,(H,16,20)(H,18,19)/t11-/m0/s1
|
| Chemical Name |
(2S)-4-cyclohexyloxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1710 mL | 15.8549 mL | 31.7098 mL | |
| 5 mM | 0.6342 mL | 3.1710 mL | 6.3420 mL | |
| 10 mM | 0.3171 mL | 1.5855 mL | 3.1710 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
